Abbott Laboratories
ABT
$135.08
-$2.63-1.91%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 13.40B | 5.77B | 5.56B | 5.63B | 5.72B |
| Total Depreciation and Amortization | 3.22B | 3.22B | 3.25B | 3.24B | 3.24B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.16B | 802.00M | 802.00M | 793.00M | 770.00M |
| Change in Net Operating Assets | -9.22B | -1.07B | -1.71B | -2.52B | -2.48B |
| Cash from Operations | 8.56B | 8.73B | 7.90B | 7.14B | 7.26B |
| Capital Expenditure | -2.21B | -2.24B | -2.25B | -2.22B | -2.20B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | -51.00M | -877.00M | -877.00M |
| Divestitures | 1.00M | 1.00M | 1.00M | 40.00M | 40.00M |
| Other Investing Activities | -132.00M | -55.00M | -40.00M | -39.00M | -94.00M |
| Cash from Investing | -2.34B | -2.30B | -2.34B | -3.10B | -3.13B |
| Total Debt Issued | 223.00M | 244.00M | 243.00M | 23.00M | 23.00M |
| Total Debt Repaid | -760.00M | -1.11B | -2.66B | -2.58B | -2.50B |
| Issuance of Common Stock | 264.00M | 273.00M | 237.00M | 239.00M | 167.00M |
| Repurchase of Common Stock | -1.30B | -1.24B | -490.00M | -913.00M | -1.23B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -3.84B | -3.77B | -3.69B | -3.62B | -3.56B |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.40B | -5.60B | -6.36B | -6.86B | -7.09B |
| Foreign Exchange rate Adjustments | -96.00M | 12.00M | -53.00M | -67.00M | -23.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 720.00M | 849.00M | -848.00M | -2.88B | -2.99B |
